OncoMatch/Clinical Trials/NCT04861077
Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)
Is NCT04861077 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies [18F]FMISO-PET with contrast-enhanced MRI for triple negative breast cancer.
Treatment: [18F]FMISO-PET with contrast-enhanced MRI — This clinical study will investigate the utility of Fludeoxyglucose (18F) fluoromisonidazole (FMISO), in patients diagnosed with triple negative breast cancer (stage II-IV disease), to monitor and predict the effect of immunotherapy. This is a parallel imaging study to current treatment strategies and no clinical decisions or outcomes will be based on the imaging. If promising, this data will be used to design larger trials. A total of 20 patients will be recruited for this study. This trial will not designate the participant's treatment plan; they will be eligible based on their treatment plan designated from their oncologist.
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) (>50%)
>50%Programmed death-ligand 1 (PD-L1) positive
Disease stage
Required: Stage II, III, IV
Prior therapy
Cannot have received: immunotherapy
Have received immunotherapy in the neoadjuvant or adjuvant setting
Lab requirements
Kidney function
adequate creatinine clearance per institutional guidelines and within 30 days
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UAB · Birmingham, Alabama
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify